esc心衰lixinli.pptVIP

Evidence supporting the mandate for ? blockade in the treatment of chronic heart failure. Mortality results from the US Carvedilol Programme, the Second Cardiac Insufficiency Bisoprolol Study (CIBIS-II), and the Metoprolol CR/XL Randomised Intervention Trial in Heart Failure (MERIT-HF). Risk reductions for mortality were highly significant in all three trials: 65% in the US Carvedilol Programme and 34% in both CIBIS-II and MERIT-HF. Wiek Van Gilst Wiek Van Gilst 心衰病人ACEI实际应用指南(7) 肾功能恶化 Some rise in urea (blood urea nitrogen), creatinine and potassium is to be expected after initiation of